title: Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP).
abstract: We report two patients with myopathy associated with anti-signal recognition particle Ab, refractory to conventional therapy, who were treated with prednisone and plasma exchange, followed by rituximab. A marked response was observed in both patients, with partial to complete recovery of muscle strength, which was sustained.
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, Cochin Hospital, Paris-Descartes University, Assistance Publique-Hôpitaux de Paris, AP-HP, Paris, France.
authors.forename: Jean-Benoit
authors.initials: JB
authors.lastname: Arlet
authors.forename: Dalia
authors.initials: D
authors.lastname: Dimitri
authors.forename: Christian
authors.initials: C
authors.lastname: Pagnoux
authors.forename: Olivier
authors.initials: O
authors.lastname: Boyer
authors.forename: Thierry
authors.initials: T
authors.lastname: Maisonobe
authors.forename: François-Jérome
authors.initials: FJ
authors.lastname: Authier
authors.forename: Coralie
authors.initials: C
authors.lastname: Bloch-Queyrat
authors.forename: Claire
authors.initials: C
authors.lastname: Goulvestre
authors.forename: Farhad
authors.initials: F
authors.lastname: Heshmati
authors.forename: Marielle
authors.initials: M
authors.lastname: Atassi
authors.forename: Loïc
authors.initials: L
authors.lastname: Guillevin
authors.forename: Serge
authors.initials: S
authors.lastname: Herson
authors.forename: Olivier
authors.initials: O
authors.lastname: Benveniste
authors.forename: Luc
authors.initials: L
authors.lastname: Mouthon
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002985:Clinical Protocols / Q000592:standards; D018450:Disease Progression; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D008297:Male; D018482:Muscle, Skeletal / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology; D009135:Muscular Diseases / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D010951:Plasma Exchange / Q000379:methods*; D011241:Prednisone / Q000008:administration & dosage*; D000069283:Rituximab; D018271:Signal Recognition Particle / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D007155:Immunologic Factors; D018271:Signal Recognition Particle; D000069283:Rituximab; D011241:Prednisone